DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0071884 A1 Page Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0071884 A1 Page Et Al US 2017.007 1884A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0071884 A1 Page et al. (43) Pub. Date: Mar. 16, 2017 (54) METHODS FOR TREATING BACTERIAL (30) Foreign Application Priority Data INFECTIONS May 1, 2013 (AU) ................................ 201390.1517 (71) Applicant: Neoculi Pty Ltd., Burwood (AU) Publication Classification (72) Inventors: Stephen Page, Newton (AU); Sanjay (51) Int. Cl Garg, Adelaide (NZ) A6II 3/55 (2006.01) A6IR 9/00 (2006.01) (21) Appl. No.: 15/363.523 (52) U.S. Cl. CPC .......... A61K 31/155 (2013.01); A61K 9/0014 (22) Filed: Nov. 29, 2016 (2013.01); A61K 9/0053 (2013.01) (57) ABSTRACT Related U.S. Application Data The invention comprises methods for treating and prevent (63) Continuation of application No. 14/888.289, filed on ing a bacterial infection in a Subject, methods for preparing Oct. 30, 2015, now Pat. No. 9,539,223, filed as a medication for use in treating and preventing a bacterial application No. PCT/AU2014/000480 on May 1, infection in a subject, and pharmaceutical and Veterinary 2014. antibacterial compositions when used therein. Patent Application Publication Mar. 16, 2017. Sheet 1 of 31 US 2017/0071884 A1 888 estig - 888; 8.8:3 s: 8 ses: 2 8s: : s:s: 2 aara Sagi, stress 8& 8 8. xx 33. ... ... Figtre : Patent Application Publication Mar. 16, 2017. Sheet 2 of 31 US 2017/0071884 A1 I ::::::::::::::::::::: i 8:88:88-838: ------'os-osssssssssss------------ $3:8: 3 ::::::: 838.3383 Aaaaaaaaaaaa- 88:8x. '',3:3: :...: 88:3388M-NMWowows'-ow'ssesssssssooooooo-o-o- 838.33: & 3333 w woxxess----------------- igire 2 Patent Application Publication Mar. 16, 2017. Sheet 3 of 31 US 2017/0071884 A1 Patent Application Publication Mar. 16, 2017. Sheet 4 of 31 US 2017/0071884 A1 aaaaaaaaaa --arrara-araara-a-amy------- ---. resssssssssssss -----, Bacteria hio. stics vicse vic tie fatige isolates 8xxie. gigs ----------------------------------- 4 (8-128 4 x 38 4 (1) 42 4 (1) {{}} 4 (3. {{:} &A NA x& . grewmonia& 4 (<0.25 4 (0.25) 4 (<0.25); : ...'......--------------------------------------..................----------------------------------------------............ xixie - 8x8 8:38 c{xxxix. 8:88: 8:38. xix. $ 8x8::::::::::::::::::::::::8 &:8: 8:8 sixx:::::::::::::::::::::. Figare & Stagigiococess {888.88: 88.888 & c. 2923 3:Six:----------Yssessssssssssssssssssssssswwwow---------------------- iii. Patent Application Publication Mar. 16, 2017. Sheet 5 of 31 US 2017/0071884 A1 E8& Systie &3 *:::::::: figure 8 RNA Synthesis § ****$3&#######% ii. 8: Figtre Patent Application Publication Mar. 16, 2017. Sheet 6 of 31 US 2017/0071884 A1 Protein Synthesis X. saxYx exia Systhesis Figures 8 Patent Application Publication Mar. 16, 2017. Sheet 7 of 31 US 2017/0071884 A1 gic Systies is 380 88: 3. && & 8.x &x xx xyce 8excess c s' - ' ' ' ' . 88.88. igire is x -ik Syrresis x 8-ix Synthesis ** * {xte: &y 88ss 8. ix. Systesis - Ce was Synthesis "; o six: igris : Patent Application Publication Mar. 16, 2017. Sheet 8 of 31 US 2017/0071884 A1 8 * *::::::: xis: : : 8. : 8. 8 " " ' ". {x}: 888: 8:iii-xi{ *igare : Patent Application Publication Mar. 16, 2017. Sheet 9 of 31 US 2017/0071884 A1 ***3.38#3.8±. *********?x3333*******wº?4×4×3×333|333sos?3×3×3;&&&& ***$$$$*** ---.-.-.-.-.-.;********************************************************************* Patent Application Publ ication Mar. 16, 2017. Sheet 10 Of 31 US 2017/0071884 A1 3×33){ 33333 3.’’.No.ž,#33 ********** *** Patent Application Publication Mar. 16, 2017. Sheet 11 of 31 US 2017/0071884 A1 ;---.-.-.-.-.-.-.-.-.-.-.-.-*************************** %{}{} ·š······---··········---··········---····~~~~~~ %06||%004%06% Patent Application Publication Mar. 16, 2017. Sheet 12 of 31 US 2017/0071884 A1 % % g4.******** ********************************************::::· Patent Application Publication Mar. 16, 2017. Sheet 13 of 31 US 2017/0071884 A1 g4.******* 3×3×3×3×3×3*************)33333333333&#####2×2×3338&#333;x??¢&#ø33x3x3&3&& *************************** --------------------------------------------+--------------------------~--~~~~~~--~~~~~~~~~~~~~~---------------------?-------------------------~--~~~~~~~~~~*,*)*,,,, Patent Application Publication Mar. 16, 2017. Sheet 14 of 31 US 2017/0071884 A1 -:: . W. ... ... ................. ............. ................................... : : : 8 388x g888 ce:83. *igure Patent Application Publication Mar. 16, 2017. Sheet 15 of 31 US 2017/0071884 A1 % 8;&####3 Patent Application Publication Mar. 16, 2017. Sheet 16 of 31 US 2017/0071884 A1 Essgassis; 3 8::it::::::::::::tory isit: sax:8&isixia: assics}:sia ages: (xx888tatics gi: &&888traigs: gigs: {88. (xi sciatest8st8xi 8&ress 8:8 88s. 88: 888 88&s NC 332 Airp::::::: 388-8 8.33 8 s X- ra Ncisix is a 8 4-8. 8 8 Arpic:8: S-8:38 88 x:23 883 3-3. 3 : 2-4 3. 3. Arap::it: 8-88 88 :S a. -- Nicaia 8-8 k 8 2-8 8 stagic:8: 8.2x38 : 888 8. X w igers $8 Patent Application Publication Mar. 16, 2017. Sheet 17 of 31 US 2017/0071884 A1 : 8 : x3.33 :::::::::::::::::::::: 3. x * :::::::::::... 8: 3. 38. 3. «38:g: Xi.-8:3 : Six:e 8888. *igtse 38 : 3. is: 88s figure 3 Patent Application Publication Mar. 16, 2017. Sheet 18 of 31 US 2017/0071884 A1 333333&z 33:33,8 ---------------------§§§). Patent Application Publication Mar. 16, 2017. Sheet 19 of 31 US 2017/0071884 A1 *8x383383 §.33%| TOE ? Patent Application Publication Mar. 16, 2017. Sheet 20 of 31 US 2017/0071884 A1 C8 Apicii vexia {{sic x: {{xit got 8 x: irre irs *igar833 . 8 x 38 giant. Šigits. 2.8 33 gigs. :::::g;8. 8. ' & iii. 4;giai. 2 ::gjiai. .8 3.3 gigi. 3.8: 3.38:g;8. 88: ::::::: ite is *igtse 38 Patent Application Publication Mar. 16, 2017. Sheet 21 of 31 US 2017/0071884 A1 * :::::::::::::. -x. 8:88: Patent Application Publication Mar. 16, 2017. Sheet 22 of 31 US 2017/0071884 A1 38 x 33:g8.s 3: w8- 8:::::::. 88::::8: 8:883: & 8 xxxxx 3 is 2s 2.8 s is is a is is: {:8: Patent Application Publication Mar. 16, 2017. Sheet 26 of 31 US 2017/0071884 A1 x 33:8:3. 3 x 333 ::::::::. as st ::::: *x. 8888 :::::::: . 388 is is: 838 8: t: 88 grex: 888 38: 833.838 8:388 38 Patent Application Publication Mar. 16, 2017. Sheet 27 of 31 US 2017/0071884 A1 be : figure 3 Patent Application Publication Mar. 16, 2017. Sheet 28 of 31 US 2017/0071884 A1 --s:-------------------- ------ 8 s: xe --------- -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 33.338.......ww. gg&#####3 *...*.*.*.*.*.*.*.*.*.*¿.**************************~~~~---------···? : ----- sessss-s-s-s-s Patent Application Publication Mar. 16, 2017. Sheet 29 of 31 US 2017/0071884 A1 #--~~~~~*~~~~ 44-444 ------- Yaaaaaaaaaaaaaa-a-a-a-a-a-a-a-a-a-a- Patent Application Publication Mar. 16, 2017. Sheet 30 of 31 US 2017/0071884 A1 M&m ::::::::::: w8 &{3. 833 (83:::::::: ... : : - 83.883 : 338g:::::: 883 : 338 ::::::::: . s : s: r -- S.& 3. 8 & Patent Application Publication Mar. 16, 2017. Sheet 31 of 31 US 2017/0071884 A1 --cers & 8. 3. 3. 8 & 8 8. 888 &sis: *igs: 8 (3.3 -- ex : 8 & s: & *igt's 33 US 2017/007 1884 A1 Mar. 16, 2017 METHODS FOR TREATING BACTERIAL Soft tissue lesions as well as a rapid, fulminating, necrotizing INFECTIONS pneumonia with significant associated mortality. Recently MRSA strains have become host-adapted in several key TECHNICAL FIELD animal species including livestock, horses and companion 0001. This invention relates to methods of treating and animals and regular cases of human-to-animal and animal preventing a bacterial infection in a subject, methods for to-human transfer are being documented. This has important preparing a medicament for use in treating and preventing a consequences for strain transmission and public health. A bacterial infection in a Subject, and pharmaceutical and recent survey of 751 Australian veterinarians for MRSA nasal carriage found that a remarkable 21.4% of equine veterinary antibacterial compositions when used therein. veterinarians were MRSA-positive compared to 4.9% of BACKGROUND ART small animal veterinarians and 0.9% of veterinarians with little animal contact. These ecological shifts of MRSA 0002. A marked increase in prevalence of multi-drug together with the emergence of resistance to new drugs resistance in disease-causing Gram-positive (G+ve) developed specifically for MRSA such as linezolid confirm (Staphylococcus aureus, Enterococcus spp. and Streptococ that new MRSA anti-infectives are urgently needed. Fur cus pneumoniae) and Gram negative (G-ve) pathogens thermore, hospitals that use Vancomycin for treating MRSA (Escherichia coli, Enterobacter spp., Salmonella spp., then have to contend with outbreaks of Vancomycin-resistant Acinetobacter baumanni, Klebsiella pneumoniae and enterococci (VRE) infections in their patients, once again Pseudomonas aeruginosa) has coincided with an unprec with limited alternative antimicrobial choices. edented global decline in investment in new anti-infective drugs. There are few currently registered alternatives for 0006. The global emergence and spread within the com multidrug resistant (MDR) bacterial infections, forcing cli munity of highly virulent MDR Gram-negative (G-ve) nicians to consider older generation drugs such as colistin bacteria such as E. coli O25b:ST131 confirms that bacterial with narrow spectrum and considerable potential for toxic pathogens can simultaneously evolve both virulence and side-effects. In addition, there are fewer novel classes of resistance determinants. Echoing recent MRSA epidemiol antiinfective therapeutics moving through the drug devel ogy, E. coli O25b:ST131, a major cause of urinary tract and opment pipeline. bloodstream
Load more

Recommended publications
  • A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the Light of Present Day Context
    Section Pharmaindustry Commentary A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the light of Present Day Context Prashant Tandon1, Varun Gupta2, Ashish Ranjan3, Purav Gandhi4, Anand Kotiyal5, 3 Aastha Kapoor 3 1Founder ;2VP & Head Medical Affair; Manager Medical Affair; 5Drug Data Analyst Medical Affair, 1mg Technologies Private Limited, 4th Floor, Motorola Building, MG Road, Sector 14, Gurugram, Haryana, 122001. 4Founder, Remedy Social, C/602, Tulip Citadel, Shreyas Tekra, Ambawadi, Ahmedabad 380015, Gujarat. ABSTRACT______________________________________________________________ Background: Current classification of medicines in Conclusions: We have recommended a revised drug India under Drug and Cosmetic Act into Schedule G, classification system that is more comprehensive in coverage and H, H1, X is outdated, evolved through patchwork over eliminates the overlaps between classes. Moreover, considering the years and needs to be thoroughly updated. The the implementation challenges for such a drug classification primary aim of the scheduling system is to ensure system in the diverse and fragmented ecosystem in India, we appropriate access to medicines while balancing recommend a technology backed platform to help monitor the public health and safety. India is experiencing a rapid implementation. transition with the rising burden of chronic non- communicable diseases where regular access of Key words: Drug Classification System, Drug and Cosmetic Act affordable medicines is critical for chronic disease India, Digitization of Prescriptions, Drug Schedules in India, management to prevent complications. Methods: We Schedule H, Monitoring Drug Schedule System analyzed drugs commonly selling across India, Received: 01.09.17 | Accepted:16.09.17 through multiple information sources including 1mg drug database, PharmaTrac (AIOCD-AWACS), Corresponding Author inventory data from distributors and retailers, Dr.
    [Show full text]
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • Quantitative Analysis of Spectinomycin and Lincomycin in Poultry Eggs by Accelerated Solvent Extraction Coupled with Gas Chromatography Tandem Mass Spectrometry
    foods Article Quantitative Analysis of Spectinomycin and Lincomycin in Poultry Eggs by Accelerated Solvent Extraction Coupled with Gas Chromatography Tandem Mass Spectrometry Bo Wang 1,2, Yajuan Wang 2,3, Xing Xie 4, Zhixiang Diao 2,3, Kaizhou Xie 2,3,*, Genxi Zhang 2,3 , Tao Zhang 2,3 and Guojun Dai 2,3 1 College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China; [email protected] 2 Joint International Research Laboratory of Agriculture & Agri-Product Safety, Yangzhou University, Yangzhou 225009, China; [email protected] (Y.W.); [email protected] (Z.D.); [email protected] (G.Z.); [email protected] (T.Z.); [email protected] (G.D.) 3 College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China 4 Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China; [email protected] * Correspondence: [email protected]; Tel.: +86-139-5275-0925 Received: 30 March 2020; Accepted: 13 May 2020; Published: 18 May 2020 Abstract: A method based on accelerated solvent extraction (ASE) coupled with gas chromatography tandem mass spectrometry (GC-MS/MS) was developed for the quantitative analysis of spectinomycin and lincomycin in poultry egg (whole egg, albumen and yolk) samples. In this work, the samples were extracted and purified using an ASE350 instrument and solid-phase extraction (SPE) cartridges, and the parameters of the ASE method were experimentally optimized. The appropriate SPE cartridges were selected, and the conditions for the derivatization reaction were optimized. After derivatization, the poultry egg (whole egg, albumen and yolk) samples were analyzed by GC-MS/MS.
    [Show full text]
  • Determination of the Effects That a Previously Uncharacterized Secreted Product from Klebsiella Pneumoniae Has on Citrobacter Fr
    East Tennessee State University Digital Commons @ East Tennessee State University Undergraduate Honors Theses Student Works 5-2017 Determination of the effects that a previously uncharacterized secreted product from Klebsiella pneumoniae has on Citrobacter freundii and Enterobacter cloacae biofilms Cody M. Hastings Follow this and additional works at: https://dc.etsu.edu/honors Part of the Bacteria Commons, Bacteriology Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and Developmental Biology Commons, Medical Cell Biology Commons, Medical Microbiology Commons, Microbial Physiology Commons, and the Pathogenic Microbiology Commons Recommended Citation Hastings, Cody M., "Determination of the effects that a previously uncharacterized secreted product from Klebsiella pneumoniae has on Citrobacter freundii and Enterobacter cloacae biofilms" (2017). Undergraduate Honors Theses. Paper 419. https://dc.etsu.edu/ honors/419 This Honors Thesis - Withheld is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Determination of the effects that a previously uncharacterized secreted product from Klebsiella pneumoniae has on Citrobacter freundii and Enterobacter cloacae biofilms By Cody Hastings An Undergraduate Thesis Submitted in Partial Fulfillment of the Requirements
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Nigerian Veterinary Journal 39(3)
    Nigerian Veterinary Journal 39(3). 2018 Asambe et al. NIGERIAN VETERINARY JOURNAL ISSN 0331-3026 Nig. Vet. J., September 2018 Vol 39 (3): 199 -208. https://dx.doi.org/10.4314/nvj.v39i3.3 ORIGINAL ARTICLE In Vitro Comparative Activity of Ciprofloxacin and Enrofloxacin against Clinical Isolates from Chickens in Benue State, Nigeria Asambe, A.1*; Babashani, M2. and Salisu, U. S.1 ¹.Federal University Dutsinma, Katsina State. 2.Ahmadu Bello University Zaria. *Corresponding author: Email: [email protected]; Tel No:+2348063103254 SUMMARY This study compares the in vitro activities of enrofloxacin and its main metabolite ciprofloxacin against clinical Escherichia coli and non-lactose fermenting enterobacteria isolates from chickens. Ten (10) Escherichia coli and 8 non lactose fermenting enterobacteriaceae species isolated from a pool of clinical cases at the Microbiology Laboratory of the Veterinary Teaching Hospital, University of Agriculture Makurdi were used in this study. Ten-fold serial dilution of 10 varying concentrations (0.1-50μg/mL) of enrofloxacin and ciprofloxacin were tested against the isolates in vitro by Bauer’s disc-diffusion method to determine and compare their antimicrobial activities against the isolates. The 18 isolates tested were susceptible to both enrofloxacin and ciprofloxacin, and their mean values in the susceptibility of Escherichia coli and non-lactose fermenters were significantly different (p < 0.01). The study concluded that the clinical isolates are susceptible to both enrofloxacin and ciprofloxacin though ciprofloxacin exhibit higher activity. Comparatively, ciprofloxacin was found to be more potent than enrofloxacin and the difference statistically significant. Ciprofloxacin was recommended as a better choice in the treatment of bacterial infections of chicken in this area compared to enrofloxacin.
    [Show full text]
  • Bordetella Petrii Clinical Isolate Isolates of This Species Have Been Previously Reported from 4
    routine laboratory protocols. Initial susceptibility testing Bordetella petrii using disk diffusion indicated apparent susceptibility of the isolate to erythromycin, gentamicin, ceftriaxone, and Clinical Isolate piperacillin/tazobactam. The isolate was resistant to amox- icillin, co-amoxiclav, tetracycline, clindamycin, ciproflo- Norman K. Fry,* John Duncan,* Henry Malnick,* xacin, and metronidazole. After initial sensitivity results, a Marina Warner,* Andrew J. Smith,† 6-week course of oral clarithromycin (500 mg, 8 hourly) Margaret S. Jackson,† and Ashraf Ayoub† was begun. We describe the first clinical isolate of Bordetella petrii At follow-up appointments 3 months and 6 months from a patient with mandibular osteomyelitis. The only pre- after antimicrobial drug therapy ceased, clinical and radi- viously documented isolation of B. petrii occurred after the ographic findings were not unusual, and the infected area initial culture of a single strain from an environmental healed successfully. Despite the successful clinical out- source. come, the isolate was subsequently shown to be resistant to clarithromycin in vitro (Table). Improvement of the 67-year-old man visited an emergency dental clinic, osteomyelitis may also have been facilitated by the biopsy Awhere he complained of toothache in the lower right procedure, during which a sequestrum of bone was mandibular quadrant. Examination showed a root-filled removed. lower right canine tooth that was mobile and tender to per- The gram-negative bacillus (designated strain cussion. The tooth was extracted uneventfully under local GDH030510) was submitted to the Health Protection anesthesia. The patient returned after several days with Agency, Centre for Infections, London, for identification. pain at the extraction site. A localized alveolar osteitis was Preliminary tests results were consistent with those diagnosed, and local debridement measures were institut- described for members of the genus Bordetella.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Fluoroquinolones for Treating Tuberculosis (Presumed Drug- Sensitive) (Review)
    Fluoroquinolones for treating tuberculosis (presumed drug- sensitive) (Review) Ziganshina LE, Titarenko AF, Davies GR This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 6 http://www.thecochranelibrary.com Fluoroquinolones for treating tuberculosis (presumed drug-sensitive) (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 6 METHODS ...................................... 6 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 ADDITIONALSUMMARYOFFINDINGS . 15 DISCUSSION ..................................... 20 Figure3. ..................................... 20 Figure4. ..................................... 21 AUTHORS’CONCLUSIONS . 23 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 24 CHARACTERISTICSOFSTUDIES . 30 DATAANDANALYSES. 60 Analysis 1.1. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome1Deathfromanycause. 61 Analysis 1.2. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome2TB-relateddeath.
    [Show full text]
  • Detection and Partial Molecular Characterization of Rickettsia and Bartonella from Southern African Bat Species
    Detection and partial molecular characterization of Rickettsia and Bartonella from southern African bat species by Tjale Mabotse Augustine (29685690) Submitted in partial fulfillment of the requirements for the degree MAGISTER SCIENTIAE (MICROBIOLOGY) in the Department of Microbiology and Plant Pathology Faculty of Natural and Agricultural Sciences University of Pretoria Pretoria, South Africa Supervisor: Dr Wanda Markotter Co-supervisors: Prof Louis H. Nel Dr Jacqueline Weyer May, 2012 I declare that the thesis, which I hereby submit for the degree MSc (Microbiology) at the University of Pretoria, South Africa, is my own work and has not been submitted by me for a degree at another university ________________________________ Tjale Mabotse Augustine i Acknowledgements I would like send my sincere gratitude to the following people: Dr Wanda Markotter (University of Pretoria), Dr Jacqueline Weyer (National Institute for Communicable Diseases-National Health Laboratory Service) and Prof Louis H Nel (University of Pretoria) for their supervision and guidance during the project. Dr Jacqueline Weyer (Centre for Zoonotic and Emerging diseases (Previously Special Pathogens Unit), National Institute for Communicable Diseases (National Heath Laboratory Service), for providing the positive control DNA for Rickettsia and Dr Jenny Rossouw (Special Bacterial Pathogens Reference Unit, National Institute for Communicable Diseases-National Health Laboratory Service), for providing the positive control DNA for Bartonella. Dr Teresa Kearney (Ditsong Museum of Natural Science), Gauteng and Northern Region Bat Interest Group, Kwa-Zulu Natal Bat Interest Group, Prof Ara Monadjem (University of Swaziland), Werner Marias (University of Johannesburg), Dr Francois du Rand (University of Johannesburg) and Prof David Jacobs (University of Cape Town) for collection of blood samples.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Human Case of Bartonella Alsatica Lymphadenitis
    LETTERS (6). The sequence is distinct from a DOI: 10.3201/eid1412.080944 Human Case of small number of sequences derived from rabies viruses in Vietnam, which References Bartonella alsatica suggests that China is a stronger can- Lymphadenitis 1. Smith JS, Fishbein DB, Rupprecht CE, didate for the source of the virus than Clark K. Unexplained rabies in three To the Editor: Lymph node en- her native country. immigrants in the United States: a vi- Although the case history could rologic investigation. N Engl J Med. largement is a common medical prob- not provide evidence for interaction 1991;324:205–11. lem that is usually caused by bacterial, 2. Grattan-Smith PJ, O’Regan WJ, Ellis PS, with a dog while her family was in viral, fungal, or protozoal agents (1). O’Flaherty SJ, McIntyre PB, Barnes CJ. A Malignancies or lymphoproliferative Hong Kong Special Administrative second Australian case, with a long incuba- Region, rabies was endemic within tion period. Med J Aust. 1992;156:651–4. diseases are often found, especially in the colony at the time that the pa- 3. McColl KA, Gould AR, Selleck PW, elderly patients (1). Bartonella hense- Hooper PT, Westbury HA, Smith JS. tient’s family was resident. From 1980 lae, the main causative agent of cat- Polymerase chain reaction and other labo- scratch disease (CSD), appears to be through 1984, 5 human cases were re- ratory techniques in the diagnosis of long corded (9). Only 2 case-patients had incubation rabies in Australia. Aust Vet the most common organism respon- clear evidence of a dog bite; histories J.
    [Show full text]